Mentari Therapeutics (MTRI) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mentari Therapeutics is the larger company by market cap ($856.9 million vs $785.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTRI | SNDX |
|---|---|---|
| Share price | $14.70 | $8.72 |
| Market cap | $856.94M | $785.05M |
| 1-day change | -3.57% | -4.49% |
| YTD return | — | -58.50% |
| 1-year return | — | -50.00% |
| 5-year return | — | -47.09% |
| EPS (TTM) | — | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | — | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $23.30 | $25.59 |
| 52-week low | $5.75 | $8.41 |
| Distance from 52-week high | -36.91% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +306.54% |
| Average volume | 19.42K | 2.63M |
| Shares outstanding | 58.30M | 90.03M |
| Employees | — | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mentari Therapeutics
MTRI stock →Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
Health Care · Biotechnology: Pharmaceutical Preparations
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
MTRI vs SNDX FAQ
Which is bigger, Mentari Therapeutics or Syndax Pharmaceuticals?
Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $785.05M for Syndax Pharmaceuticals (SNDX).
Are Mentari Therapeutics and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.